Tectonic Therapeutic (TECX) Stock
Biotech company developing gene therapies for rare genetic diseases. Here's the price, business snapshot, and what's worth knowing about Tectonic Therapeutic in October 2026.
AVROBIO Inc (TECX) is a small-cap, clinical-stage biotechnology company focusing on gene therapy approaches for rare genetic diseases. With a market capitalisation of about $355.34M, it is typical of development-stage biotechs: value is heavily influenced by clinical trial results, regulatory milestones and financing activity. Investors should expect elevated volatility and binary events — positive trial data or approval can drive sharp gains, while setbacks or funding needs can cause steep declines. Key considerations include the strength of clinical data, manufacturing and scale-up capability, partnerships and cash runway. Gene therapies carry distinct regulatory and commercial challenges, including complex manufacturing and long-term safety monitoring. This overview is educational and not investment advice; consider your risk tolerance, investment horizon and the potential for dilution and loss of capital before investing, and consult a financial professional for personalised guidance.
Tectonic Therapeutic (TECX) Stock Forecast
Analyst price target, next 12 months
$74.78
+231.8% vs today's $22.54
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Tectonic Therapeutic have a consensus 12-month target of $74.78, above the current price of $22.54.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying Tectonic Therapeutic's stock due to significant potential for growth.
Financial Health
Tectonic Therapeutic Inc. shows strong financial performance with healthy cash flow and solid book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Milestones Ahead
Trial readouts and regulatory steps can change the outlook quickly, offering potential upside but also sharp downside if results disappoint.
Binary Event Volatility
Small-cap biotechs often move on binary news; that can create short-term trading opportunities yet also significant risk for longer-term investors.
Manufacturing & Access
Commercialising gene therapies requires scalable manufacturing and payer acceptance, which are crucial to long-term value and remain sources of uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
